...
首页> 外文期刊>British journal of ophthalmology >Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus.
【24h】

Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus.

机译:一项双盲随机试验比较了0.05%甲喹嗪滴眼液与0.05%左卡巴司汀和安慰剂在由角质层性皮炎引起的结膜激发试验引起的过敏性结膜炎中的功效和耐受性。

获取原文
获取原文并翻译 | 示例

摘要

Aim: A double masked randomised trial comparing 0.05% mequitazine eye drops with 0.05% levocabastine and placebo was carried out in otherwise heatlhy volunteers allergic to house dust mites (Dermatophagoides pteronyssinus). METHOD: Double masked, randomised, single centre study, comparing three parallel treatment groups. 60 healthy adults with a confirmed history of allergic conjunctivitis to house dust mites for at least 2 years were included and completed the trial. Conjunctival provocation tests (CPT) were done at screening, at visit 2 (V2) (1 week later), and at visit 3 (V3) (2 weeks after V2). Treatment was instilled in the same eye, 5 minutes after the CPT at V2, and twice daily until V3. CPT were scored 5, 10, 15, and 60 minutes after instillation of the dose of Dermatophagoides pteronyssinus antigen determined at inclusion (V2, curative test) or resulting in positivity (V3, preventive test) RESULTS: In the V2 (curative) test the difference between the active treatments and placebo on the redness+itching scores was not significant. At the V3 (preventive) CPT there was a lower number of reactions at the threshold dose with mequitazine (20%) compared to placebo (60%, p = 0.01) or levocabastine (45%, p = 0.10). CONCLUSION: This trial failed to clearly demonstrate curative superiority of topical antihistamines with placebo, when a single dose of treatment was instilled following CPT. However mequitazine 0.05% eye drops were superior to placebo in preventing a reaction to CPT, after 2 weeks of treatment.
机译:目的:在一个对室内尘螨(Dermatophagoides pteronyssinus)过敏的健康志愿者中进行了一项双掩盖的随机试验,将0.05%的美喹他嗪滴眼液与0.05%的左卡巴汀和安慰剂进行了比较。方法:双掩蔽,随机,单中心研究,比较三个平行治疗组。纳入了60名具有确定的过敏性结膜炎病史并居住至少2年的健康成年人,并完成了该试验。在筛查,第2次访视(V2)(1周后)和第3次访视(V3)(V2后2周)进行结膜激发试验(CPT)。在CPT于V2后5分钟,然后每天两次直至V3,将治疗滴注在同一只眼中。滴注在纳入(V2,治愈性测试)或导致阳性(V3,预防性测试)时确定的剂量的鹿角皮癣抗原剂量后5、10、15和60分钟对CPT进行评分。结果:在V2(治愈性)测试中积极治疗与安慰剂之间的发红+瘙痒评分差异不显着。在V3(预防性)CPT下,与安慰剂(60%,p = 0.01)或左卡巴汀(45%,p = 0.10)相比,在阈剂量下与甲喹嗪(20%)发生的反应次数更少。结论:CPT后滴注单剂治疗时,该试验未能清楚地证明局部抗组胺药与安慰剂的治疗优越性。然而,在治疗2周后,美喹他嗪0.05%滴眼液在预防CPT反应方面优于安慰剂。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号